Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel T Arcari

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Bioorganic & Medicinal Chemistry Letters|April 25, 2016
Optimization of amide-based EP3 receptor antagonistsEsther C Y Lee, Kentaro Futatsugi, Joel T Arcari, et al.
Organic Letters|September 14, 2011
One-pot (1-ethoxycarbonylcyclopropyl)triphenylphosphonium tetrafluoroborate ring-opening and Wittig reactionSeung Won Chung, Mark S Plummer, Laura A McAllister, et al.
The Journal of Antibiotics|December 4, 2014
Discovery and characterization of a novel class of pyrazolopyrimidinedione tRNA synthesis inhibitorsJustin I Montgomery, James F Smith, Andrew P Tomaras, et al.
Journal of Medicinal Chemistry|June 13, 2013
Pyridone-conjugated monobactam antibiotics with gram-negative activityMatthew F Brown, Mark J Mitton-Fry, Joel T Arcari, et al.
Bioorganic & Medicinal Chemistry Letters|April 10, 2013
Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumorsJoel T Arcari, Jean S Beebe, Martin A Berliner, et al.
Bioorganic & Medicinal Chemistry Letters|August 16, 2012
Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infectionsMark J Mitton-Fry, Joel T Arcari, Matthew F Brown, et al.
Journal of Medicinal Chemistry|December 20, 2011
Potent inhibitors of LpxC for the treatment of Gram-negative infectionsMatthew F Brown, Usa Reilly, Joseph A Abramite, et al.
Journal of Medicinal Chemistry|April 30, 2024
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19Charlotte M N Allerton, Joel T Arcari, Lisa M Aschenbrenner, et al.
Journal of Medicinal Chemistry|February 28, 2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main ProteaseJamison B Tuttle, Christophe Allais, Charlotte M N Allerton, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Bioorganic & Medicinal Chemistry Letters|April 25, 2016
Optimization of amide-based EP3 receptor antagonistsEsther C Y Lee, Kentaro Futatsugi, Joel T Arcari, et al.
Organic Letters|September 14, 2011
One-pot (1-ethoxycarbonylcyclopropyl)triphenylphosphonium tetrafluoroborate ring-opening and Wittig reactionSeung Won Chung, Mark S Plummer, Laura A McAllister, et al.
The Journal of Antibiotics|December 4, 2014
Discovery and characterization of a novel class of pyrazolopyrimidinedione tRNA synthesis inhibitorsJustin I Montgomery, James F Smith, Andrew P Tomaras, et al.
Journal of Medicinal Chemistry|June 13, 2013
Pyridone-conjugated monobactam antibiotics with gram-negative activityMatthew F Brown, Mark J Mitton-Fry, Joel T Arcari, et al.
Bioorganic & Medicinal Chemistry Letters|April 10, 2013
Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumorsJoel T Arcari, Jean S Beebe, Martin A Berliner, et al.
Bioorganic & Medicinal Chemistry Letters|August 16, 2012
Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infectionsMark J Mitton-Fry, Joel T Arcari, Matthew F Brown, et al.
Journal of Medicinal Chemistry|December 20, 2011
Potent inhibitors of LpxC for the treatment of Gram-negative infectionsMatthew F Brown, Usa Reilly, Joseph A Abramite, et al.
Journal of Medicinal Chemistry|April 30, 2024
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19Charlotte M N Allerton, Joel T Arcari, Lisa M Aschenbrenner, et al.
Journal of Medicinal Chemistry|February 28, 2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main ProteaseJamison B Tuttle, Christophe Allais, Charlotte M N Allerton, et al.
Pageof 1